Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Guadecitabine (SGI-110) Plus Nivolumab in Refractory CIMP+ Metastatic Colorectal Cancer

NCT03576963 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03576963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Guadecitabine (SGI-110) Plus Nivolumab in Refractory CIMP+ Metastatic Colorectal Cancer
Lead sponsor
University of Southern California
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 30, 2020
Completion date
January 30, 2023
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, cpg island methylator phenotype, metastatic microsatellite stable colorectal carcinoma, refractory colorectal carcinoma, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8